Strengths and weaknesses of pneumococcal conjugate vaccines.


Journal

Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310

Informations de publication

Date de publication:
04 2023
Historique:
received: 22 11 2022
accepted: 09 01 2023
revised: 24 11 2022
pubmed: 19 1 2023
medline: 23 3 2023
entrez: 18 1 2023
Statut: ppublish

Résumé

Multivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes. Notwithstanding its undoubtable success, some weaknesses have called for continuous improvement of pneumococcal vaccination. For instance, despite their inclusion in pneumococcal conjugate vaccines, there are challenges associated with some serotypes. In particular, Streptococcus pneumoniae type 3 remains a major cause of invasive pneumococcal disease in several countries.Here a deep revision of the strengths and weaknesses of the licensed pneumococcal conjugate vaccines and other vaccine candidates currently in clinical development is reported.

Identifiants

pubmed: 36652051
doi: 10.1007/s10719-023-10100-3
pii: 10.1007/s10719-023-10100-3
pmc: PMC10027807
doi:

Substances chimiques

Pneumococcal Vaccines 0
Vaccines, Conjugate 0
Antibodies, Bacterial 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-148

Informations de copyright

© 2023. The Author(s).

Références

Cell. 2004 May 28;117(5):677-87
pubmed: 15163414
Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20
pubmed: 19366365
Nat Rev Immunol. 2006 Nov;6(11):849-58
pubmed: 17024229
Clin Infect Dis. 2018 Jun 18;67(1):42-49
pubmed: 29324986
J Biol Chem. 2011 Oct 14;286(41):35813-35822
pubmed: 21859716
Heliyon. 2016 Nov 29;2(11):e00198
pubmed: 27957553
Vaccine. 2017 Mar 1;35(9):1293-1298
pubmed: 28161425
Clin Infect Dis. 2021 Oct 5;73(7):e1489-e1497
pubmed: 32716500
Infect Immun. 2001 Feb;69(2):787-93
pubmed: 11159969
Immunobiology. 2013 Mar;218(3):368-72
pubmed: 22704520
Expert Rev Vaccines. 2017 Dec;16(12):1181-1190
pubmed: 29130395
PLoS One. 2013 Sep 12;8(9):e72588
pubmed: 24069152
Vaccine. 2022 Jul 29;40(31):4190-4198
pubmed: 35690500
Clin Infect Dis. 2019 May 30;68(12):2135-2143
pubmed: 30357326
PLoS Pathog. 2017 Jan 30;13(1):e1006137
pubmed: 28135322
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
Expert Rev Vaccines. 2011 Mar;10(3):307-22
pubmed: 21434799
Lancet Infect Dis. 2004 Mar;4(3):144-54
pubmed: 14998500
ACS Cent Sci. 2018 Mar 28;4(3):357-361
pubmed: 29632881
Infect Immun. 1982 Jul;37(1):89-103
pubmed: 7107011
J Infect Dis. 2001 Sep 15;184(6):789-93
pubmed: 11517443
mBio. 2020 May 19;11(3):
pubmed: 32430472
Nat Rev Microbiol. 2008 Apr;6(4):288-301
pubmed: 18340341
Hum Vaccin. 2011 Oct;7(10):1012-8
pubmed: 21941097
Clin Vaccine Immunol. 2015 Dec 16;23(2):162-7
pubmed: 26677201
Carbohydr Res. 2003 Nov 14;338(23):2531-8
pubmed: 14670714
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12896-12901
pubmed: 30559195
Clin Infect Dis. 2022 Aug 31;75(3):390-398
pubmed: 34940806
Vaccine. 2021 Sep 7;39(38):5428-5435
pubmed: 34315611
Chem Sci. 2020 Jun 26;11(28):7401-7407
pubmed: 34123020
mBio. 2016 Jun 07;7(3):
pubmed: 27273824
N Engl J Med. 2015 Mar 19;372(12):1114-25
pubmed: 25785969
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):13353-13358
pubmed: 30530654
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13564-9
pubmed: 23898212
Public Health Rep. 2016 Jan-Feb;131(1):11-6
pubmed: 26843664
Vaccine. 2021 May 27;39(23):3197-3206
pubmed: 33965258
PLoS Med. 2010 Oct 05;7(10):
pubmed: 20957191
Vaccine. 2016 Mar 18;34(13):1540-1550
pubmed: 26899372
ACS Chem Biol. 2021 Sep 17;16(9):1671-1679
pubmed: 34469105
Russ J Bioorg Chem. 2021;47(1):1-25
pubmed: 33776393
Curr Opin Immunol. 2020 Aug;65:42-49
pubmed: 32361591
Cell Chem Biol. 2016 Nov 17;23(11):1407-1416
pubmed: 27818299
J Am Chem Soc. 2017 Oct 18;139(41):14783-14791
pubmed: 28945368
Pediatrics. 2006 Sep;118(3):865-73
pubmed: 16950975
Drugs. 2022 Jun;82(9):989-999
pubmed: 35793027
Vaccine. 2018 Nov 26;36(49):7479-7486
pubmed: 30385056
Can J Infect Dis Med Microbiol. 2016;2016:5381871
pubmed: 27366170
Clin Vaccine Immunol. 2012 Aug;19(8):1296-303
pubmed: 22739693
J Infect Dis. 2008 Apr 1;197(7):1016-27
pubmed: 18419539
Front Mol Biosci. 2022 Aug 08;9:961532
pubmed: 36003080
Expert Rev Vaccines. 2010 Mar;9(3):229-36
pubmed: 20218848
Vaccine. 2011 Nov 15;29(49):9127-31
pubmed: 21983361
Elife. 2018 Dec 28;7:
pubmed: 30592459
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1143-51
pubmed: 25699685
BMC Infect Dis. 2010 Feb 10;10:22
pubmed: 20146815
Annu Rev Immunol. 1995;13:655-92
pubmed: 7612238
Microbiol Spectr. 2019 Mar;7(2):
pubmed: 30977464
J Immunol. 2002 Dec 1;169(11):6149-53
pubmed: 12444118
Hum Vaccin Immunother. 2019;15(3):530-539
pubmed: 30648919
Expert Rev Vaccines. 2020 Jan;19(1):57-70
pubmed: 31903805
Lancet Infect Dis. 2016 Jun;16(6):703-711
pubmed: 26897105
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075
pubmed: 31751323
Hum Vaccin Immunother. 2016;12(2):383-92
pubmed: 26535755
Vaccine. 2021 Dec 17;39(51):7494-7502
pubmed: 34839993
Clin Microbiol Infect. 2010 May;16(5):411-8
pubmed: 20132250
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
J Biol Chem. 2010 Jul 30;285(31):24217-27
pubmed: 20507989
Curr Opin Microbiol. 2012 Apr;15(2):194-203
pubmed: 22280885
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11063-11068
pubmed: 28973947
BMC Infect Dis. 2022 Mar 26;22(1):294
pubmed: 35346092
Genes (Basel). 2019 Oct 25;10(11):
pubmed: 31731573
Carbohydr Res. 2015 Apr 10;406:27-33
pubmed: 25658063
Lancet Infect Dis. 2011 Oct;11(10):760-8
pubmed: 21621466
Pulm Pharmacol Ther. 2015 Jun;32:124-9
pubmed: 24607597
Semin Immunol. 2020 Aug;50:101433
pubmed: 33309166
Nat Microbiol. 2020 Mar;5(3):473-485
pubmed: 32015499
Sci Transl Med. 2017 Mar 8;9(380):
pubmed: 28275152
J Immunol. 2013 Sep 15;191(6):3254-63
pubmed: 23926322
Vaccines (Basel). 2020 Mar 17;8(1):
pubmed: 32192117
Medicine (Baltimore). 2016 Sep;95(37):e4854
pubmed: 27631247
Lancet Child Adolesc Health. 2018 Aug;2(8):561-568
pubmed: 30119715
MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):893-7
pubmed: 16163262
PLoS Pathog. 2007 Mar;3(3):e32
pubmed: 17367207
Eur J Immunol. 2005 Feb;35(2):352-6
pubmed: 15682450
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897
J Clin Microbiol. 1995 Oct;33(10):2759-62
pubmed: 8567920
Sci Rep. 2016 Apr 22;6:24931
pubmed: 27103188
Pediatr Infect Dis J. 2017 Dec;36(12):e334-e340
pubmed: 28650416

Auteurs

Francesca Micoli (F)

GSK Vaccines Institute for Global Health, Siena, Italy. francesca.x.micoli@gsk.com.

Maria Rosaria Romano (MR)

GSK Vaccines, Siena, Italy.

Filippo Carboni (F)

GSK Vaccines, Siena, Italy.

Roberto Adamo (R)

GSK Vaccines, Siena, Italy.

Francesco Berti (F)

GSK Vaccines, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH